ArticleAnnals of the rheumatic diseases2002

Treatment of refractory antibody mediated autoimmune disorders with an anti-CD20 monoclonal antibody (rituximab).

K Arzoo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.